21 reports

FEB ##, 2017: SENSORION PRESENTS POSTER ON ITS DRUG CANDIDATE, SENS-##, AT ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY ANNUAL MEETING Sensorion, a biotech company specializing in the treatment of inner ear diseases, provided details of the poster presentation given on SENS-## at the ##th A

  • Ear, Nose, And Throat Medicine
  • Europe
  • World
  • Product Initiative
  • Sensorion S.A.

According to the American Academy of Otolaryngology, the total cost of a cochlear implant, including everything from evaluation to rehabilitation, can be as much as $##, ##.

  • Ear, Nose, And Throat Medicine
  • Forecast
  • Carl Zeiss AG
  • Danaher Corporation
  • Olympus Corporation
  • Corporate Communications
  • Auris Medical Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD60.7 Million

He is dual board certified in Otolaryngology and Neurotology by the American Board of Otolaryngology.

  • Ear, Nose, And Throat Medicine
  • United States
  • Company
  • Corporate Finance
  • Auris Medical Holding AG
  • Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting

Lustig, MD, Chair, Department of Otolaryngology at Columbia University Medical Center.

  • Ear, Nose, And Throat Medicine
  • Pathology
  • Therapy
  • United States
  • Otonomy, Inc.

He is dual board certified in Otolaryngology and Neurotology by the American Board of Otolaryngology.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • United States
  • Product Initiative
  • Auris Medical Holding AG
  • Mar 04, 2011: Auris Medical's AM-111 Protects against Hearing Loss from Cochlear Implant Electrode Insertion Trauma
  • May 04, 2015: Auris Medical Holding Provides Update on Clinical Development Plan for AM-111

Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, provided an update on the clinical development of its AM-## product candidate.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Therapy
  • United States
  • Product Initiative
  • 5.2.3 BY REGION
  • is enabling people to purchase the technologically
  • Ear, Nose, And Throat Medicine
  • Europe
  • North America
  • World
  • Market Size

Audigy is a preeminent US based provider of business and performance management solutions to independent hearing care, otolaryngology, otology and neurotology practices and leading University programs in North America.

  • Ear, Nose, And Throat Medicine
  • World
  • Forecast
  • Cochlear Limited
  • Sonova Holding AG
  • Aug 03, 2017: Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Published OTIPRIO Phase ## Results in JAMA Otolaryngology - Head & Neck Surgery: In January, extensive data from clinical trials supporting FDA approval of OTIPRIO for use during pediatric TTP surgery were published in JAMA Otolaryngology - Head & Neck Surgery.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • United States
  • Company
  • Otonomy, Inc.
  • 8.4.3 RECENT DEVELOPMENTS

Audigy is a preeminent US based provider of business and performance management solutions to independent hearing care, otolaryngology, otology and neurotology practices and leading University programs in North America.

  • Ear, Nose, And Throat Medicine
  • World
  • Forecast
  • RION Co., Ltd
  • Sonova Holding AG

HARTNICK, A PROFESSOR OF OTOLARYNGOLOGY AT HARVARD MEDICAL SCHOOL AND CHIEF OF PEDIATRIC OTOLARYNGOLOGY AT MASSACHUSETTS EYE AND EAR INFIRMARY AND MASSACHUSETTS GENERAL HOSPITAL, HAS JOINED IN PAVMED' S MEDICAL ADVISORY BOARD AND WILL WORK CLOSELY WITH THE PAVMED TEAM ON DEVELO

  • Ear, Nose, And Throat Medicine
  • United States
  • Company
  • Company Financials
  • GlobalData's company
  • Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
  • Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere Disease

Lustig, MD, Chair, Department of Otolaryngology at Columbia University Medical Center.

  • Ear, Nose, And Throat Medicine
  • Pathology
  • Therapy
  • United States
  • Otonomy, Inc.
  • Apr 20, 2012
  • FEATURED NEWS & PRESS RELEASES

Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, provided an update on the clinical development of its AM-## product candidate.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • United States
  • World
  • Product Initiative

Associate Professor of Otolaryngology and Co-Director of the Head and Neck Cancer Program in the NCI Comprehensive-Designated Dan L.

  • Ear, Nose, And Throat Medicine
  • Sexually Transmitted Disease
  • Vaccine
  • United States
  • Advaxis, Inc.
  • Jun 17, 2016: Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness
  • May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111

In March 2011, New research data presented at the recent Midwinter Meeting of the Association for Research in Otolaryngology (ARO) provided further evidence of AM-##' s otoprotective effects, Auris Medical AG' s new intracellular drug for the treatment of inner ear disorders.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • World
  • Product Initiative
  • Auris Medical Holding AG
  • 9.2 References

American Academy of Otolaryngology.

  • Ear, Nose, And Throat Medicine
  • Health Services
  • Healthcare
  • World
  • Novartis AG
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Otolaryngology Head and Neck Surgery Duke University ## May 2007 ## Jun 2009 ## ## ## ## ## Muscarinic Acetylcholine Receptor M## (CHRM##) Agonist; Muscarinic Acetylcholine Receptor M## (CHRM##) Agonist Muscarinic Acetylcholine Receptor M## (CHRM##); Muscarinic Acetylcholine Receptor M## (CHRM##) Cl

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Lung Cancer
  • Monoclonal Antibody
  • Merck & Co., Inc.

Head and neck cancer

4546 5000 3864
  • Epidemiologist Insight

Otolaryngology - Head and Neck Surgery, ##(##), ##-## < DOI> ##. ##/ j. otohns. 2006. ##. ##< / DOI>. de Souza DLB, Bernal Pérez MM, Curado MP (2011) Predicted incidence of oral cavity, oropharyngeal, laryngeal, and hypopharyngeal cancer in Spain and implications for cance

  • Ear, Nose, And Throat Medicine
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • 3. GDCT ID IS THE UNIQUE ID OF GLOBALDATA'S PHARMA INTELLIGENCE CENTER CLINICAL TRIAL DATABASE

Otolaryngology Head and Neck Surgery Duke University ## May 2007 ## Jun 2009 ## ## ## ## ## Muscarinic Acetylcholine Receptor M## (CHRM##) Agonist; Muscarinic Acetylcholine Receptor M## (CHRM##) Agonist Muscarinic Acetylcholine Receptor M## (CHRM##); Muscarinic Acetylcholine Receptor M## (CHRM##) Cl

  • Cancer
  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • United States
  • World

Otolaryngology Physician ##-##-## Seoul Asan Medical Center SK Chemicals Co., Ltd.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • World
  • Product Initiative
  • Sensorion S.A.
  • Clinical Trial Profile Snapshots

Associate Professor of Otolaryngology and co-director of the Head and Neck Cancer Program in the NCI Comprehensive-Designated Dan L.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • World
  • Product Initiative
  • Merck & Co., Inc.